AUDREY SCHILLING: Open Payments
NPI 1225405590 · STARKVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,528 in 80 payments from 20 companies in 2025. Trend: 2023 $1,356 · 2024 $1,998 · 2025 $1,528
Food & beverage: $1,528
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $231 |
| Novo Nordisk Inc | 13 | $220 |
| AstraZeneca Pharmaceuticals LP | 10 | $213 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $211 |
| Lilly USA, LLC | 10 | $173 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $81 |
| Astellas Pharma US Inc | 3 | $64 |
| Averitas Pharma Inc. | 2 | $52 |
| Abbott Laboratories | 2 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
Products named: CAPLYTA, MOUNJARO, AIRSUPRA, Wegovy, UBRELVY, Kerendia, FARXIGA, Ozempic.
Industry payments across MS — which companies pay providers there.
